Overview

Webcast ImageWebcast
Clovis Oncology, Inc. at the 34th Annual J.P. Morgan Healthcare Conference (Replay)
01/13/16 at 11:00 a.m. PT
Clovis Oncology, Inc. at the 34th Annual J.P. Morgan Healthcare Conference
Wednesday, January 13, 2016 11:00 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicine – More >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$18.60
Change (%) Stock is Down 0.38 (2.00%)
Intraday High$19.05
Intraday Low$17.90
Volume620,362
Data as of 02/11/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
01/27/16Clovis Oncology Initiates Immunotherapy Combination Trial
Study to evaluate the combination of rociletinib (CO-1686) with Genentech’s atezolizumab (MPDL3280A) for patients with advanced EGFR-mutant non-small cell lung cancer BOULDER, Colo.--(BUSINESS WIRE)--Jan. 27, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it initiated a clinical trial to evaluate a novel combination therapy of Genentech’s investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PD-L1) and rociletini... 
Printer Friendly VersionDownload PDF
01/25/16Clovis Oncology Appoints Dale Hooks as Chief Commercial Officer
Hooks, Clovis’ Vice President of Sales since 2014, has been instrumental in building out the Company’s commercial organization BOULDER, Colo.--(BUSINESS WIRE)--Jan. 25, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Dale Hooks has been named Senior Vice President and Chief Commercial Officer. Mr. Hooks succeeds Steve Hoerter, the Company’s current Chief Commercial Officer and Executive Vice President, who is leaving to pursue other ... 
Printer Friendly VersionDownload PDF
01/06/16Clovis Oncology to Present at the 34th Annual J.P. Morgan Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 6, 2016-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016 at 11:00 AM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A live webcast of the presentation can be accessed through the investor r... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.